Showing 2011-2020 of 2105 results for "".
- Positive Results for Ublituximab in Phase 2 Clinical Trialhttps://practicalneurology.com/news/positive-results-for-ublituximab-in-phase-2-clinical-trial/2468815/Patients with relapsing-remitting multiple sclerosis (RRMS) who were treated with ublituximab (TG Therapeutics, New York, NY) (n = 46) had rapid depletion of B cells, reduced disease activity on MRI, markedly lower relapse rate, and disability stability. Ublituximab (UTX) is a novel glycoengineer
- Rates of Initiating Disease-Modifying Treatment for Multiple Sclerosis Remain Lowhttps://practicalneurology.com/news/rates-of-initiating-disease-modifying-treatment-for-multiple-sclerosis-remain-low/2468819/Research suggests that as many as 43% of patients with multiple sclerosis (MS) do not take a disease-modifying treatment (DMT) for the first 2 years of their diagnosis or longer. In a retrospective claims analysis using the IQVIA adjudicated claims database from June 2010 to June, 2017.
- Expanded Access to Free Genetic Testing for Children with Epilepsyhttps://practicalneurology.com/news/expanded-access-to-free-genetic-testing-for-children-with-epilepsy/2468824/Eligibility for a program that provides free genetic testing for epilepsy in young children has been expanded. The Behind the Seizure program, which had been available for patients age 2 to 4 years with a history of 1 or more unprovoked seizures, is now offered for children from birth to age 5 ye
- Deep Brain Stimulator for Medically-Refractory Epilepsy Now Available in UShttps://practicalneurology.com/news/deep-brain-stimulator-for-medically-refractory-epilepsy-now-available-in-us/2468828/Deep brain stimulation (DBS) with the Medtronic DBS System (Medtronic, Dublin, Ireland) was approved by the Food and Drug Administration (FDA) last year and is now available in the US on a commercial basis. The first patient to receive the device commercially had it implanted at Emory University
- Lemborexant Use Does Not Affect Next-Day Driving Performancehttps://practicalneurology.com/news/lemborexant-use-does-not-affect-next-day-driving-performance/2468862/In a phase 1 safety study, healthy adult volunteers, mean age 58.5 (age range 23-78 years), who took lemborexant (Eisai, Woodcliff Lake, NJ and Purdue, Stamford, CT) at bedtime, had no impairment of driving performance the next morning compared with volunteers who took placebo. Results of th
- FDA Approves Generic Vigabatrin for Complex Partial Seizureshttps://practicalneurology.com/news/fda-approves-generic-vigabatrin-for-complex-partial-seizures/2468865/January 21, 2019—The Food and Drug Administration (FDA) has approved generic vigabatrin 500 mg tablets for adjunctive treatment of patients with complex partial seizures, age 10 years and older, who have not responded adequately to other treatments. “We know there has been
- New Study Will Evaluate Smart Watch Technology for Help in Preventing Strokeshttps://practicalneurology.com/news/new-study-will-evaluate-smart-watch-technology-for-help-in-preventing-strokes/2468864/January 21, 2019—A new study will analyze the impact of a smart watch (Apple, Cupertino, CA) on early detection and diagnosis of atrial fibrillation (AFib) and the potential to prevent stroke. The large-scale research will start later this year in the US and will be a pragmatic, randomized,
- Joon Y. Kang, MDhttps://practicalneurology.com/profiles/joon-y-kang-md/jmx1Y0/
- Patrick Y. Wen, MDhttps://practicalneurology.com/profiles/patrick-y-wen-md/jPKDXr/
- Benjamin W. Y. Lo, MDhttps://practicalneurology.com/profiles/benjamin-w-y-lo-md/O91Go2/